Hodgkin lymphoma arise from B-lymphocytes. However, classical markers of the B-cell phenotype, such as CD20, are present only in about 25% of the cases. The aim of the present study was to assess expression of the B-cell-related antigens CD20, CD79a, and CD138 in classical Hodgkin lymphoma using a tissue microarray consisting of 330 classical Hodgkin lymphoma cases. Expression of CD15, CD20, CD30, CD79a, CD138, and latent membrane protein 1 of Epstein-Barr virus was assessed by immunohistochemistry, and the methodology was validated by direct comparison of CD20 expression on the tissue microarray cores with corresponding large sections. The influence of the number of arrayed sample cores on the obtained expression levels of CD20 was analyzed by comparing the results from single, duplicate, and triplicate cores. Twohundred fifty-three (77%) of the 330 cases were morphologically representative. CD20 was expressed in 84 cases (33%), CD79a in 26 (10%), and CD138 in 2 (1%), respectively. CD20 and CD79a were co-expressed in 16 cases (P < .005), and expression of CD20 correlated inversely with CD15 (P < (9, 10, 13, 15, 16, 18 -22). Typically, CD20 appears to be expressed on a variable proportion of Hodgkin and Reed-Sternberg cells with variable staining intensity, often weaker than in normal reactive B cells (9, 15, 20) . Positivity for CD20 in classical Hodgkin lymphoma can lead to serious diagnostic difficulties in the differential diagnosis of nodular lymphocytepredominant Hodgkin lymphoma and T-cell-rich B-cell lymphoma, two clinically distinct but morphologically closely related diseases (8, 9, 23) . Moreover, expression of CD20 has become also of clinical interest: Rituximab seems to be an efficient treatment option for relapsed CD20-positive Hodgkin lymphoma (24), and we have recently demonstrated that CD20-positive classical Hodgkin lymphoma cases have better failure-free and overall survival (18).
Recent molecular studies showed that Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma originate from germinal center or postgerminal B cells (1) (2) (3) (4) (5) (6) (7) (8) (9) . Phenotypic examinations revealed that 5 to 100% of Hodgkin and ReedSternberg cells in classical Hodgkin lymphoma express different B-cell markers, such as CD19, CD20, CD40, CD79a, CD138, bcl-6, B-cell specific activator protein (PAX5), and MUM1 . Expression of the classical B-cell marker CD20 in classical Hodgkin lymphoma reportedly varied from 5% to Ͼ80% (9, 10, 13, 15, 16, 18 -22) . Typically, CD20 appears to be expressed on a variable proportion of Hodgkin and Reed-Sternberg cells with variable staining intensity, often weaker than in normal reactive B cells (9, 15, 20) .
Positivity for CD20 in classical Hodgkin lymphoma can lead to serious diagnostic difficulties in the differential diagnosis of nodular lymphocytepredominant Hodgkin lymphoma and T-cell-rich B-cell lymphoma, two clinically distinct but morphologically closely related diseases (8, 9, 23) . Moreover, expression of CD20 has become also of clinical interest: Rituximab seems to be an efficient treatment option for relapsed CD20-positive Hodgkin lymphoma (24) , and we have recently demonstrated that CD20-positive classical Hodgkin lymphoma cases have better failure-free and overall survival (18) .
Immunohistochemical studies revealed that other markers of B-cell differentiation, such as CD79 and CD138, also known as syndecan-1, are expressed on Hodgkin and Reed-Sternberg cells in 10 to 48%, and 45 to 100% of cases, respectively; however, expression of CD138 has been studied exclusively on frozen tissue (1-3, 11, 12, 21) .
The tissue microarray technique allows simultaneous analysis of a large number of tumors for in situ expression of individual markers under highly standardized conditions (25, 26) . Recently, its accuracy has been proven for a variety of markers, such as CD5, CD10, CD15, CD20, CD23, CD30, CD43, CD44, bcl-2, bcl-6, p53, cyclin D1, cyclin D3, cyclin E, and the latent membrane protein 1 of EpsteinBarr virus, clearly demonstrating that it is also a reliable tool for the analysis of large lymphoma populations (27) (28) (29) (30) . We previously reported the largest classical Hodgkin lymphoma-tissue microarray yet constructed and validated its representativeness for predominantly homogenously and/or consistently expressed markers on a large proportion of Hodgkin and Reed-Sternberg cells, such as latent membrane protein 1 and CD30 (30) . This tissue microarray, comprised of 330 classical Hodgkin lymphoma cases of all subtypes, was now used to analyze the predominantly heterogeneously and inconsistently expressed B-cell markers on Hodgkin and Reed-Sternberg cells such as CD20, CD79a, and CD138 and to correlate them to CD15, which is typically also inconsistently expressed both in individual cells and individual cases, and latent membrane protein 1.
MATERIALS AND METHODS

Samples
Three hundred thirty classical Hodgkin lymphoma cases collected between 1985 and 2001 at the Institutes of Pathology at the Universities of Basel (Switzerland), Bologna (Italy), and Innsbruck (Austria) and at the Triemli Hospital of Zurich (Zurich, Switzerland) were included. All cases were reclassified according to the WHO classification (9) and consisted of 197 nodular sclerosis, 105 mixed cellularity, 5 lymphocyte depleted, 10 lymphocyterich, and 13 unclassifiable classical Hodgkin lymphoma.
Tissue Microarray Constructions
For tissue microarray construction, a hematoxylin and eosin-stained slide was made from each block to define representative tumor regions, particularly Hodgkin and Reed-Sternberg cell hot spots, if present. Tissue cylinders (cores) with a diameter of 0.6 mm were punched from the tumor areas of each block and brought into a recipient paraffin block using a precision instrument (Beecher Instruments, Silver Spring, MD), as described elsewhere (25, 26) . Five-micrometer sections of these tissue microarray blocks were transferred to an adhesive-coated glass slide system (Instrumedics Inc., Hackensack, NJ). To overcome the problem of tissue microheterogeneity and increase the number of evaluable cases, we punched the donor tissue blocks either two (Innsbruck and Basel samples) or three times (Bologna and Zurich samples). Only tissue cores containing at least two unequivocal Hodgkin and Reed-Sternberg cells were considered representative. Cases with only one pathognomonic cell were excluded from further examination. In addition, morphology was corroborated by CD30 immunostains.
Immunohistochemistry
Bound secondary antibodies were visualized by standard avidin-biotin-peroxidase techniques using diaminobenzidine as chromogen (ABC-Elite; Vector Lab., Burlingame, CA). Deparaffinization with xylene and incubation with the primary antibody lasted 24 hours. Antibodies against CD15, CD20, CD30, CD79a, and CD138, their dilutions and pretreatment conditions, are listed in Table 1 . For the B-cell markers CD20, CD79a, and CD138, staining in Ͼ10% of Hodgkin and Reed-Sternberg cells or in Ͼ50% of the Hodgkin and Reed-Sternberg cells (cases with Ͻ10 tumor cells) was considered positive (18) . For positive control staining, normal tonsils (CD20, CD79a, and CD138) were used. For negative control experiments, the primary antibodies were omitted.
Statistics
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS).
2 was applied to estimate the interrelations between the (Table 2 ). CD20 staining was weak to moderate compared with the strongly stained reactive B-lymphocytes in the background and was confined to the cell membrane of the Hodgkin and Reed-Sternberg cells with a submembranous rim (Fig. 2C-D) . In positive cases, 20 to 90% of Hodgkin and Reed-Sternberg cells expressed CD20 (median, 40%). There was no significant correlation between Epstein-Barr virus infection and expression of CD20 in Hodgkin and Reed-Sternberg cells (P ϭ .055). However, expression of CD20 correlated inversely with CD15 expression: 37/167 CD15-positive cases (22%) expressed CD20, versus 47/86 (55%) CD20-positive cases in the CD15-negative group (P Ͻ .01). Twenty-six cases (10%) expressed CD79a ( Table 2) . In these cases, 10 to 30% of Hodgkin and ReedSternberg cells expressed CD79a (median, 20%), with moderate staining intensity localized to the cell membrane and the cytoplasm (Fig. 2E-F) . In 16 cases, Hodgkin and Reed-Sternberg cells coexpressed CD20 and CD79a (P Ͻ .005; Fig. 3 ). CD138 was expressed in two cases (1%) that were negative for CD20 and CD79a, with a moderate staining intensity in about half of the Hodgkin and Reed-Sternberg cells, and strongly stained plasma cells were scattered throughout the background infiltrate ( Fig. 2G-H) . Altogether, 96 of the 253 classical Hodgkin lymphoma cases (38%) expressed at least one B-cell marker.
To assess the influence of the number of arrayed cores from the same tissue specimen on the tissue microarray sensitivity, we compared the results for expression of CD20 and CD79a of single, duplicate, and triplicate cores, the latter for the cases of Bologna and Zurich (n ϭ 88) that were punched three times as explained in our Materials and Methods. Examination of one random core showed average expression ratios of 24% for CD20 (61/253) and 7% for CD79a (18/253), respectively. Examination of two cores significantly increased these values, to 32% and 10% (82/253 and 25/253, P Ͻ .0001), respectively. Evaluation of all three cores augmented the previous values only incrementally, by 1% and 0.5% (84/253 and 26/253, P Ͼ 0.1), respectively (Fig. 4) .
To validate the classical Hodgkin lymphomatissue microarray methodology, we directly compared CD20 expression on the tissue microarray to that assessed on conventional full tissue sections in 68 cases (all from Innsbruck). Seventeen of 67 evaluable cases (25%) were positive on the tissue microarray compared with 21 (31%) on the full tissue sections. Ninety-four percent (63/67) of the cases were concordant. Six percent (4/67), all containing Ͻ10 Hodgkin and Reed-Sternberg cells per two cores, were discordant, that is, positive for CD20 on conventional sections and negative on the tissue microarray. The -value was 0.85, indicating an excellent concordance.
DISCUSSION
Although the B-cell origin of Hodgkin and ReedSternberg cells in classical Hodgkin lymphoma is now well established (1-9), the frequency of immunohistochemically detectable expression of classical B-cell markers remains controversial. For example, CD20-expression in various studies ranges from 5 to Ͼ80% (9, 10, 13, 15, 16, 18 -22) . The discrepancy between the obvious genotypic B-cell origin of classical Hodgkin lymphoma and the lack of phenotypically demonstrable B-cell marker expression can be explained by molecular alterations leading not only to down-regulation of single B-lineage markers but to profound defects in B-lineage gene expression (31, 32) .
Using the novel tissue microarray technology, we found CD20 expression in 33% of our large series of 253 classical Hodgkin lymphomas, a distribution in line with the results of other studies performed on conventional large sections (9, 10, 13, 15, 16, 18 -22) . Moreover, direct validation demonstrated that the expression of CD20 on the tissue microarray matched in 94% (63/67) the corresponding conventional full tissue sections. This result is even better than the 83% concordance for CD20 reported recently by Garcia and coworkers (27) . In our study, discordances due to decreased sensitivity were observed in 4 cases (6%), all with Ͻ10 Hodgkin and Reed-Sternberg cells per two tissue microarray cores. This can be explained by the known focal expression of CD20 in classical Hodgkin lymphoma in a median proportion of approximately 50% of the Hodgkin and Reed-Sternberg cells (9, 10, 13, 15, 16, 18 -22) . All matching cases contained Ͼ30 Hodgkin and Reed-Sternberg cells per two tissue microarray cores. Obviously, for the most critical combination of focally expressed markers (CD20) in heterogeneous tumors (classical Hodgkin lymphoma), paucity of tumor cells on the cores can lead to decreased tissue microarray sensitivity. However, this can be largely compensated for by repeatedly punching representative tumor areas from the donor block. For comparison, we observed a concordance of 100% between the tissue microarray and conventional large sections for the expression of latent membrane protein 1, a marker that is homogenously and consistently expressed in all Hodgkin and Reed-Sternberg cells of Epstein-Barr virus-associated classical Hodgkin lymphoma (30) .
To assess in detail the influence of the number of arrayed sample cores on the representativeness of the tissue microarray, we compared the expression of CD20 and CD79a after evaluation of one (0.28 mm 2 tissue size), two (0.57 mm 2 ), and three cores (0.85 mm 2 ) from individual cases. Ninety-eight percent of the overall positivity of 33% for expression of CD20 was reached after examining at least two cores, compared with 73% after evaluation of one random core (P Ͻ .0001). Evaluation of the third core was not significantly more informative-two additional cases of 253 appeared to be CD20 positive (P ϭ .158). Similar observations were made for CD79a. Therefore, our conclusions for the use of the tissue microarray technique for classical Hodgkin lymphoma are that it is advisable to punch every tissue block of classical Hodgkin lymphoma samples at least twice and that the representativeness of the samples is not further enhanced by inclusion of multiple tissue punches in the tissue microarray.
In this large tissue microarray study, we found no correlation between expression of CD20 in classical Hodgkin lymphoma and Epstein-Barr virus infection, even when analyzed separately for cases with mixed-cellularity classical Hodgkin lymphoma, in agreement with our previous observations on a limited patient population (18) . However, we observed an inverse correlation between the distribution of CD15 and CD20 (P Ͻ .01) that remains to be elucidated.
Interestingly, despite being expressed in virtually all mature circulating B-cells and, to a lesser degree in germinal center B cells (33) , CD79a was expressed in only 10% of classical Hodgkin lymphoma, compared with 33% for CD20. This result is within the range of reports from the literature (8, Nodular sclerosis  145  141  97  102  70  41  28  11  8  26  18  Mixed cellularity  83  83  100  48  58  35  42  14  17  27  33  Lymphocyte rich  10  6  60  4  40  3  30  1  10  1  10  Lymphocyte depleted  5  5  100  4  80  1  20  -3  6 0  Unclassified  10  10  100  9  90  4  40  -3  3 0  Total  253  245  97  167  66  84  33  26  10  60  24 11, 12). CD79a is noncovalently associated with surface immunoglobulins to constitute the B-cell antigen receptor complex on the surface of mature B cells (11) . It can be speculated that down-regulated expression of CD79a in Hodgkin and ReedSternberg cells might be associated with the known lack of immunoglobulin mRNA transcription in Hodgkin and Reed-Sternberg cells because of absence of PU.1 along with Oct2 and BOB.1 (34, 35) . Only 2 of 253 classical Hodgkin lymphoma cases (1%) expressed CD138, in contrast to reported results, using frozen tissue samples, of CD138-expression in 45 to 100% of classical Hodgkin lymphoma (1, 2, 21) . Obviously, the fundamental differences in techniques account for differences in the degree of expression of CD138 and make a direct comparison impossible.
In summary, the classical B-cell markers CD20 and CD79a are expressed in 33% and 10% of classical Hodgkin lymphoma, respectively. Thirty-eight percent of classical Hodgkin lymphomas express at least one B-cell marker. Although classical Hodgkin lymphoma is considered exemplary of heterogeneous tumors not suited for tissue microarray analysis, we demonstrate that the tissue microarray technology can be reliably applied for highthroughput analyses of focally and inconsistently expressed markers if at least two cores per case are examined.
